Compare ARK Genomic Revolution ETF (ARKG) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Nutrien Ltd — how do they compare? ARK Genomic Revolution ETF trades at $40.8, while Nutrien Ltd trades at $67.36 (market cap $31.29B). The key difference: Nutrien Ltd pays a 3.36% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Nutrien Ltd nearer its low. Which is the better fit depends on your goals.
| ARKG | NTR | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $43.57 | $83.94 |
52-Week Low | $23.09 | $53.64 |
Market Cap | — | $31.29B |
Enterprise Value | — | $44.46B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Nutrien (NTR) trades at $65.43, up 1.33% today, with a neutral technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations, driven by record potash volumes. The stock shows solid fundamentals with a P/E of 13.33 and ROE of 9.7%, though revenue has declined from 2022 peaks. A dividend of $0.55 per share is scheduled for July 2026, supporting income appeal.
Outlook remains positive with a consensus price target of $80.14, reflecting 22% upside potential. Risks include volatile fertilizer prices and geopolitical impacts on agriculture markets. Institutional sentiment is bullish, with 64% of analysts rating it Buy, but investors should monitor debt levels and global demand shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
